Comparative Study of Sitagliptin and Gliclazide With Metformin in Type 2 Diabetes Patients With Glucotoxicity

Launched by ZHIBIN XU · Sep 23, 2024

Keywords

ClinConnect Summary

In this single-center, prospective, randomized controlled non-inferiority study, treatment-naïve patients with T2DM and glucotoxicity were enrolled to evaluate the comparative efficacy and safety of two therapeutic regimens. The study investigates the combination of sitagliptin phosphate with gliclazide sustained-release tablets against metformin alone. Participants were randomized and monitored for 12 weeks, with primary outcomes focusing on fasting plasma glucose (FPG) levels, body weight changes, and hypoglycemic events. The study also explores the impact of treatment on β-cell function ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Diagnosed with Type 2 Diabetes Mellitus (T2DM) and glucotoxicity.
• • Body Mass Index (BMI) between 18 and 30 kg/m².
• • Fasting plasma glucose (FPG) levels ≥ 200 mg/dL and glycated hemoglobin (HbA1c) ≥ 9.0%.
• • Normal hepatic and renal functions (ALT and AST ≤ 2.5 times the upper limit of normal; serum creatinine within normal limits).
• • Capable of adhering to the prescribed anti-diabetic regimen and dietary guidelines.
• Exclusion Criteria:
• • Diagnosis of Type 1 Diabetes Mellitus.
• • Hepatic or renal dysfunction (serum creatinine \> 1.2 times the upper limit of normal).
• • Prior use of hypoglycemic medications before screening.
• • History of severe ketosis, ketoacidosis, or hyperosmolar hyperglycemic state.
• • Current treatment with corticosteroids, immunosuppressive agents, or cytotoxic drugs.
• • Major systemic diseases (e.g., cardiovascular, respiratory, neurological).
• • Pregnant or breastfeeding women.
• • Known allergies to sitagliptin or gliclazide.
• • Poor compliance potential as assessed by the investigator.